Business
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. Poster presentation details, as follows: Title: Discovery and O
About this update from Xilio Therapeutics, Inc.
[{"type":"image","alt":"Xilio Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Xilio Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":188,"url":"https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fPzX58BffAl1ebEMXSQhaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af","width":300,"height":188}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California.","length":436,"tagName":"p"},{"type":"text","content":"Poster presentation details, as follows:","length":40,"tagName":"p"},{"type":"text","content":"Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell EngagerSession Category: ImmunologySession Title: T Cell Engagers 1Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:00 p.m. PSTLocation: Poster Section 10Poster Board: 11Abstract Number: 1619","length":299,"tagName":"p"},{"type":"text","content":"About Xilio Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn.","length":625,"tagName":"p"},{"type":"text","content":"Cautionary Note Regarding Forward-Looking Statements","length":52,"tagName":"p"},{"type":"text","content":"This press release contains...